2007.07.11 - CTI

Pre-market:

CTI - +5% gap...

"Cell Therapeutics, Inc. (CTIC) announced that interim results of its phase II/III trial comparing CPOP-R, in which pixantrone is substituted for doxorubicin in standard CHOP-R first-line treatment of patients with aggressive non-Hodgkin's lymphoma (NHL), resulted in essentially all patients on both arms achieving a major objective anti-tumor response (complete response or partial response)."

Market open:

A FONR ma is szépen mozgott, a tegnapi maximumát áttörve rátett még 10%-ot...
A SBEI tört ki szépen (+150%!!!), de nagyon alacsony az átlagforgalma...

A végén 180%-os emelkedést produkált....



Ez volt mára a tőzsde...

Market closed